A large randomized controlled trial of a monoclonal antibody targeting tau protein tangles, the other major pathological hallmark of Alzheimer's disease alongside amyloid plaques, has demonstrated a 35 percent reduction in clinical decline over 18 months compared to placebo in early Alzheimer's disease patients. The result adds to the emerging treatment paradigm combining amyloid-clearing drugs now approved with tau-targeting approaches addressing the second major pathological mechanism.
The Alzheimer's treatment landscape has transformed remarkably in the past three years following the approval of lecanemab and donanemab, the first treatments proven to slow cognitive decline. A combination approach targeting both amyloid and tau could potentially achieve greater slowing of progression than either approach alone, though combination trials have not yet produced results. The challenge of identifying suitable patients, monitoring treatment safety, and managing drug costs in a disease affecting 7 million Americans remains formidable.
